AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03195387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
Study NCT03195387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
Study NCT02350036 — intervention group
Intervention type: OTHER
Intervention: ultrasound monitoring
Description: Uterine artery Doppler assessment
Study NCT04482816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological pacing
Description: Pacing of the his bundle or the left bundle branch
Study NCT04482816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Conventional pacing; right ventricular pacing
Study NCT00922844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and isoflurane
Description: Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
Study NCT02817490 — intervention group
Intervention type: OTHER
Intervention: patient education program
Description: The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session.
Study NCT03207087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEB Aneurysm Embolization
Description: Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
Study NCT01943084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin® FlexPro® pen
Description: Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Study NCT02965144 — intervention group
Intervention type: OTHER
Intervention: no treatment
Description: no treatment
Study NCT01823120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive and interactive text messages
Study NCT01719640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of MSCs
Description: infusion of MSCs
Study NCT01719640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusion MCs
Description: infusion of MCs
Study NCT01719640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion MCs
Description: infusion of MCs
Study NCT01719640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: intensive insulin care
Study NCT01719640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: intensive insulin care
Study NCT01882062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin 1g/kg/day
Study NCT02921022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02921022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02921022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Study NCT01200719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: \< 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity \~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
Study NCT00574678 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Tear collection
Description: A tear sample (\~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed.
Study NCT01600950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Single 0.3 U/kg dose administered subcutaneously
Study NCT01600950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Single 0.3 U/kg dose administered subcutaneously
Study NCT03699046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty and Knee Arthroscopy
Description: Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
Study NCT03699046 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Knee Arthroscopy Alone
Description: Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
Study NCT03699046 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty
Description: Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
Study NCT02372448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ALK analysis on CTCs detected by ISET
Study NCT02470013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced, energy dense, moderate protein sip feed
Description: 2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
Study NCT00641043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + pioglitazone (30 mg)
Description: placebo + overcapsulated 30 mg tablet, once daily
Study NCT00641043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + pioglitazone (30 mg)
Description: 5 mg tablet + overcapsulated 30 mg tablet, once daily
Study NCT02205567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Bergamot-derived product
Description: Group 1: 500mg/day Group 2: 1000mg/day
Study NCT03399539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03399539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03399539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03399539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05074095 — intervention group
Intervention type: OTHER
Intervention: retrospective analysis
Study NCT02318394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0562
Description: Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
Study NCT03622411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speech app
Description: language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
Study NCT03622411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: brain games
Description: language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
Study NCT03622411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: language exercises provided by the speech therapist in hospital
Study NCT03622411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aphasia therapy
Description: language exercises provided by the speech therapist in hospital
Study NCT03351322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F701
Description: ENERGI-F701 are applied for treatment of hair loss.
Study NCT03351322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regaine
Description: Regaine are applied for treatment of hair loss.
Study NCT03196297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: 0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
Study NCT03196297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa
Description: Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
Study NCT03690622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Instillation of eyedrops
Study NCT03690622 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Balanced salt solution
Description: instillation of eyedrop
Study NCT02992470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed oyster extract
Description: 1 tablet of oyster extract t.i.d. for 8 weeks
Study NCT02992470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of maltodextrin t.i.d. for 8 weeks
Study NCT01227915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobracort
Description: tobramycin 0.3% + dexamethasone 1%
Study NCT01227915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobradex
Description: tobramycin 0.3% + dexamethasone 1%
Study NCT02349906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Study NCT02349906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busilvex
Study NCT01231737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prulifloxacin
Description: Prulifloxacin 1 tablet/week for 12 weeks.
Study NCT03739840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.
Study NCT05285319 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate Only Radiation
Description: Prostate Only Radiation for Intermediate and High Risk Prostate cancer
Study NCT05285319 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate and Pelvic Lymph Node Radiation
Description: Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
Study NCT04396392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based training
Description: All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to.
Study NCT04396392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR-based training
Description: All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to.
Study NCT00176722 — intervention group
Intervention type: OTHER
Intervention: table tilt
Description: One group randomized to table tilt. One group will be flat.
Study NCT01796496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy Techniques
Description: * Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction.
Study NCT03729206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: intravital microscopy
Description: intravital microscopy with sidestream dark-field imaging
Study NCT01004263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
Study NCT03464643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: embryo culture
Description: Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
Study NCT01537354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf®
Description: Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
Study NCT01537354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta®
Description: Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
Study NCT03497182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath sample collection
Description: Subject exhales into breath collection container.
Study NCT01796496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Technique
Description: The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
Study NCT03988816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500Mcg Tab, once daily
Study NCT03988816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: once daily
Study NCT00604929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate and protein
Description: The intake of carbohydrate and protein during endurance type exercise
Study NCT01034111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
Study NCT01034111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
Study NCT03640689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovenous ablation + iliac US +/- iliac stenting
Description: Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
Study NCT03640689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous ablation of Great Saphenous Vein
Description: Ablation of the Great Saphenous Vein and subsequent Graduated Compression
Study NCT02909361 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: 500 mg on days 0, 14, and 28, and every 28 days thereafter
Study NCT03254069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless Steel Crowns
Description: SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
Study NCT03180411 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes.
Study NCT03180411 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
Study NCT03553940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine
Description: Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
Study NCT03553940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
Study NCT03553940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent MDCK Inactivated Influenza Vaccine
Description: A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
Study NCT03553940 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent MDCK Inactivated Influenza Vaccine
Description: A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
Study NCT02069587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate
Study NCT04285229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT04285229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study NCT04285229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01943084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin Pen®
Description: Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.